HTRA1 and lung carcinoma: Because an even greater HTRA1 downregulation in lymph node metastases compared to the primary sites was evident in lung cancer [36] and malignant melanoma [11], this strongly points to a particular benefit for node-positive patients to have high expression of the tumor suppressor HTRA1.